Gilead Sciences Management

Management criteria checks 3/4

Gilead Sciences' CEO is Dan O'Day, appointed in Mar 2019, has a tenure of 4.5 years. total yearly compensation is $21.62M, comprised of 7.8% salary and 92.2% bonuses, including company stock and options. directly owns 0.031% of the company’s shares, worth CHF26.58M. The average tenure of the management team and the board of directors is 3.6 years and 5.1 years respectively.

Key information

Dan O'Day

Chief executive officer

US$21.6m

Total compensation

CEO salary percentage	7.8%
CEO tenure	4.5yrs
CEO ownership	0.03%
Management average tenure	3.6yrs
Board average tenure	5.1yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Dan O'Day's remuneration changed compared to Gilead Sciences's earnings?
Date	Total Compensation	Salary	Company Earnings
Jun 30 2023	n/a	n/a	US$5b
Mar 31 2023	n/a	n/a	US$6b
Dec 31 2022	US$22m	US$2m	US$5b
Sep 30 2022	n/a	n/a	US$3b
Jun 30 2022	n/a	n/a	US$4b
Mar 31 2022	n/a	n/a	US$5b
Dec 31 2021	US$19m	US$2m	US$6b
Sep 30 2021	n/a	n/a	US$7b
Jun 30 2021	n/a	n/a	US$5b
Mar 31 2021	n/a	n/a	US$301m
Dec 31 2020	US$19m	US$2m	US$123m
Sep 30 2020	n/a	n/a	US$1b
Jun 30 2020	n/a	n/a	-US$257m
Mar 31 2020	n/a	n/a	US$5b
Dec 31 2019	US$29m	US$1m	US$5b

Compensation vs Market: Dan's total compensation ($USD21.62M) is above average for companies of similar size in the Swiss market ($USD6.38M).

Compensation vs Earnings: Dan's compensation has been consistent with company performance over the past year.

CEO

Dan O'Day (59 yo)

4.5yrs

Tenure

US$21,621,253

Compensation

Mr. Daniel P. O'Day, also known as Dan, serves as Non-Executive Non-Independent Director for Galapagos NV since October 22, 2019. He served as Member of Supervisory Board at Galapagos NV since October 22,...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Daniel P. O'Day	Chairman & CEO	4.5yrs	US$21.62m	0.031% $ 26.6m
Andrew Dickinson	Executive VP & CFO	3.8yrs	US$8.40m	0.0088% $ 7.6m
Deborah Telman	Executive VP of Corporate Affairs	1.1yrs	US$4.82m	0.00052% $ 448.8k
Johanna Mercier	Chief Commercial Officer	4.2yrs	US$9.24m	0.0072% $ 6.2m
Merdad Parsey	Chief Medical Officer	3.8yrs	US$9.04m	0.0056% $ 4.9m
Sandra Patterson	Senior VP	less than a year	no data	0.0024% $ 2.1m
Jacquie Ross	Vice President of Investor Relations	2.7yrs	no data	no data
Jyoti Mehra	Executive Vice President of Human Resources	4.1yrs	no data	no data
Michael Quigley	Senior Vice President of Research Biology	3.6yrs	no data	no data
Linda Higgins	Senior Vice President of Research	3.6yrs	no data	no data
Rudolf Ertl	Senior Vice President of Commercial Operations of Australia	no data	no data	no data
Flavius Martin	Executive Vice President of Research	2.4yrs	no data	no data

3.6yrs

Average Tenure

58yo

Average Age

Experienced Management: 000935700's management team is considered experienced (3.6 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Daniel P. O'Day	Chairman & CEO	4.5yrs	US$21.62m	0.031% $ 26.6m
Anthony Welters	Independent Director	2.9yrs	US$429.93k	0.00064% $ 552.4k
Paul Berg	Member of Scientific Advisory Board	no data	US$16.00k	no data
Jacqueline Barton	Independent Director	5.7yrs	US$414.88k	0.0018% $ 1.5m
Eugene Schiff	Member of the Scientific Advisory Board	no data	no data	no data
John Mellors	Member of the Scientific Advisory Board	no data	no data	no data
Francis Chisari	Member of the Scientific Advisory Board	no data	no data	no data
Paul Klotman	Member of the Scientific Advisory Board	no data	no data	no data
Kevin Lofton	Lead Independent Director	14.2yrs	US$489.93k	0.0074% $ 6.4m
Kelly Kramer	Independent Director	7.1yrs	US$434.93k	0.00011% $ 94.9k
Joel Huff	Chairperson of Scientific Advisory Board	no data	no data	no data
Grace Colon	Chairman of the Board	less than a year	no data	no data

5.1yrs

Average Tenure

68yo

Average Age

Experienced Board: 000935700's board of directors are considered experienced (5.1 years average tenure).

Gilead Sciences Management

Management criteria checks 3/4

Key information

Recent management updates

Gilead Sciences, Inc., Annual General Meeting, May 08, 2024

Gilead Sciences, Inc. Announces Retirement of Kevin E. Lofton from the Board, Effective May 8, 2024

Gilead Sciences, Inc. Appoints Ted Love to Board of Directors

Gilead Sciences, Inc. Appoints Ted Love to Board of Directors

Bloom Science, Inc. Appoints Grace E. Colon as Chair of Its Board of Directors

Gilead Sciences, Inc. Appoints Cindy Perettie Executive Vice President of Kite

Recent updates

Gilead Sciences, Inc. Announces U.S. Food and Drug Administration Approve Biktarvy® Label Update With Data for Pregnant Adults With HIV

Gilead Sciences, Inc. to Report Q1, 2024 Results on Apr 25, 2024

Gilead Sciences, Inc., Annual General Meeting, May 08, 2024

FDA Expands Indication for Gilead's Vemlidy (Tenofovir Alafenamide) to Treat Chronic Hbv Infection in Pediatric Patients as Young as Six

Gilead Sciences, Inc. (NasdaqGS:GILD) completed the acquisition of CymaBay Therapeutics, Inc. (NasdaqGS:CBAY).

Gilead Sciences, Inc. Announces Retirement of Kevin E. Lofton from the Board, Effective May 8, 2024

Gilead and Merck Announce Phase 2 Data Showing an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression at Week 24

Gilead Sciences, Inc.'s Innovative HIV Treatment Research Pipeline Aims to Address Unmet Needs and Advance Public Health

Gilead Sciences, Inc. announced that it has received $210 million in funding from Abingworth LLP

Gilead Sciences, Inc. to Present Late-Breaking Data and Real-World Evidence Highlighting Innovative Antiviral Portfolio and Research Pipeline At CROI 2024

Gilead Sciences, Inc. (NasdaqGS:GILD) entered into an Agreement and Plan of Merger to acquire CymaBay Therapeutics, Inc. (NasdaqGS:CBAY) for $3.7 billion.

Gilead Sciences, Inc. Provides Earnings Guidance for the Full Year 2024

Gilead Sciences, Inc. Appoints Ted Love to Board of Directors

Gilead Sciences, Inc. Appoints Ted Love to Board of Directors

Gilead Sciences, Inc. to Report Q4, 2023 Results on Feb 06, 2024

Gilead Provides Update on Phase 3 Evoke-01 Study

Gilead Sciences, Inc. Announces U.S. FDA Approves Label Update for Kite’s Yescarta® CAR T-Cell Therapy to Include Overall Survival Data

Gilead Sciences, Inc. Revises Earnings Guidance for the Year 2023

Gilead Sciences, Inc. and Arcus Biosciences, Inc. Announces New Data Showing Encouraging Clinical Activity of Anti-TIGIT Domvanalimab-Containing Regimen as First-Line Treatment for Upper GI Cancers

Gilead Sciences, Inc. to Present Late Breaking Data and Real World Evidence Highlighting Key Hepatitis Indications at The Liver Meeting®? 2023

Gilead Sciences, Inc. Presents New Data Supporting Sunlenca®? (Lenacapavir) as an Important Treatment Option for Adults with Multi-Drug Resistant HIV

Gilead Sciences, Inc. Announces New Long-Term Real-World Data from BICSTaR Study Highlighting Safety and Efficacy Profile of Biktarvy as Treatment Regimen for Broad Range of People with HIV, Including Those with Prior Treatment History or Comorbidities

Gilead Sciences, Inc. Announces New Clinical Trial in Europe to Assess Lenacapavir for HIV Prevention as Part of Purpose Program

Gilead Demonstrates the Impact of Global Collaboration in Advancing Hiv Research and Health Equity At EACS 2023

Gilead Sciences, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Gilead Sciences, Inc. Announces CHMP of EMA Adopts Positive Opinion to Extend Use of Veklury (Remdesivir) to Treat COVID-19 in People with Hepatic Impairment

Kite, A Gilead Company Announces Car T-Cell Therapy Yescarta® Demonstrates High Response Rate and Durable Remission in ALYCANTE Study as Initial Treatment for Transplant Ineligible Patients with Relapsed/Refractory Large B-Cell Lymphoma

Gilead Sciences, Inc.'s Phase 2 EVOKE-02 Study of Trodelvy® (sacituzumab govitecan-hziy) in Combination With KEYTRUDA® (pembrolizumab) Demonstrates Promising Clinical Activity in First-Line Metastatic Non-Small Cell Lung Cancer

Gilead Sciences, Inc. Announces U.S. Food and Drug Administration Approval of Supplemental New Drug Application (sNDA) for the Use of Veklury (remdesivir)

Gilead Sciences, Inc. Provides Earnings Guidance for the Full Year 2023

European Commission Approves Gilead’S Trodelvy for Pre-Treated HR+/HER2- Metastatic Breast Cancer

Gilead Sciences, Inc. Presents New Data Reinforcing the Efficacy, Safety, and Tolerability Profile of Lenacapavir from the Phase 2/3 Capella Trial

Gilead Sciences, Inc. Presents New Biktarvy® Data at IAS 2023 Further Demonstrate Safety and Efficacy Profile in a Broad Range of People and Communities Affected by the Global HIV Epidemic

Gilead Sciences, Inc. to Discontinue Phase 3 ENHANCE Study of Magrolimab Plus Azacitidine in Higher-Risk MDS

Gilead Sciences, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Gilead Receives CHMP Positive Opinion for Trodelvy® in Pre-Treated HR+/HER2- Metastatic Breast Cancer

Gilead Sciences, Inc. Announces Week 96 Results from the Pivotal MYR301 Phase 3 Clinical Trial Evaluating the First-In-Class Entry Inhibitor Hepatitis Delta

Upcoming dividend of US$0.75 per share at 3.9% yield

Gilead Sciences, Inc. Announces Longer-Term Overall Survival Results from the Phase 3 Tropics-02 Study Evaluating Trodelvy® Versus Comparator Chemotherapy

Gilead Sciences, Inc. and Arcus Biosciences, Inc. Announce Anti-TIGIT Domvanalimab Continues to Demonstrate Consistent Improvement in Progression-Free Survival in Non-Small Cell Lung Cancer Study

Bloom Science, Inc. Appoints Grace E. Colon as Chair of Its Board of Directors

Gilead and Kite Oncology to Showcase Advances Across the Pipeline Aiming to Address Unmet Needs in Cancer Care At Asco 2023

Gilead Sciences, Inc. Appoints Cindy Perettie Executive Vice President of Kite

Gilead Sciences, Inc. (NasdaqGS:GILD) acquired Xinthera, Inc.

Gilead Sciences, Inc. Announces Updated Positive Results from Three Cohorts of the Phase 2 Trophy-U-01 Study of Trodelvy®

Full year 2022 earnings released: EPS: US$3.66 (vs US$4.96 in FY 2021)

Gilead Sciences, Inc. Announces U.S. FDA Approves Trodelvy in Pre-Treated HR+/HER2- Metastatic Breast Cancer

Gilead Sciences, Inc. Provides Earnings Guidance for the Full Year 2023

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age